2023 年第 12 期 第 18 卷

洛铂联合榄香烯治疗肺癌合并恶性胸腔积液的效果观察

Effect of lobaplatin combined with elemene in the treatment of lung cancer complicated with malignant pleural effusion

作者：高树会1张桂彬2闫莉1高海祥1张爱丽1许金伟1苏艳1庞博1

英文作者：Gao Shuhui1 Zhang Guibin2 Yan Li1 Gao Haixiang1 Zhang Aili1 Xu Jinwei1 Su Yan1 Pang Bo1

单位：1河北省人民医院呼吸内科，石家庄050000；2河北省人民医院胸外科，石家庄050000

英文单位：1Department of Respiratory Medicine Hebei General Hospital Shijiazhuang 050000 China； 2Department of Thoracic Surgery Hebei General Hospital Shijiazhuang 050000 China

关键词：肺癌；恶性胸腔积液；洛铂；榄香烯；胸腔灌注

英文关键词：Lungcancer;Malignantpleuraleffusion;Lobaplatin;Elemene;Intrathoracicperfusion

• 摘要：

• 目的  探讨洛铂联合榄香烯用于肺癌合并恶性胸腔积液的治疗效果。方法  选取2019年7月至2022年7月河北省人民医院肺癌合并恶性胸腔积液患者60例，按照随机数字表法将其分为对照组和观察组，每组30例。对照组给予洛铂胸腔灌注治疗，观察组联合应用洛铂与榄香烯胸腔灌注治疗，每周1次，治疗4周。比较2组患者临床疗效、生活质量评分、血清肿瘤标志物水平、胸腔积液生化指标水平及不良反应发生情况。结果  治疗后，观察组缓解率高于对照组［83.3%（25/30）比56.7%（17/30）］，差异具有统计学意义（χ2=16.847，P＜0.05）。治疗后，观察组生活质量改善率高于对照组［40.0%（12/30）比23.3%（7/30）］，差异具有统计学意义（χ2=6.446，P＜0.05）。治疗后，2组乳酸脱氢酶、血管内皮生长因子、低氧诱导因子1α水平均低于治疗前、且观察组均低于对照组；2组腺苷脱氢酶水平均高于治疗前、且观察组高于对照组，差异均有统计学意义(均P＜0.05)。观察组不良反应发生率低于对照组，差异有统计学意义（P<0.05）。结论  洛铂联合榄香烯治疗可改善肺癌合并恶性胸腔积液患者的临床症状和相关指标，提高患者生活质量，同时减轻洛铂的不良反应。

• Objective To investigate the effect of lobaplatin combined with elemene in the treatment of lung cancer complicated with malignant pleural effusion. Methods A total of 60 patients with lung cancer complicated with malignant pleural effusion in Hebei General Hospital from July 2019 to July 2022 were selected, and they were randomly divided into control group and observation group according to the random number table method, with 30 cases in each group. The control group was treated with intrathoracic perfusion of lobaplatin, and the observation group was treated with intrathoracic perfusion of lobaplatin and elemene, once a week for 4 weeks. The clinical efficacy, quality of life score, serum tumor marker levels, pleural effusion biochemical indicators and adverse reactions were compared between the two groups. Results  After treatment, the remission rate in the observation group was higher than that in the control group ［83.3%(25/30) vs 56.7%(17/30)］(χ2=16.847, P<0.05). After treatment, the improvement rate of quality of life in the observation group was higher than that in the control group ［40.0%(12/30) vs 23.3%(7/30)］(χ2=6.446, P<0.05). After treatment, the levels of lactate dehydrogenase, vascular endothelial growth factor and hypoxia inducible factor-1α in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group; the levels of adenosine dehydrogenase in the two groups were higher than those before treatment, and that in the observation group was higher than that in the control group (all P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). Conclusion Lobaplatin combined with elemene can improve the clinical symptoms and related indicators of patients with lung cancer complicated with malignant pleural effusion, improve the quality of life of patients, and reduce the adverse reactions of lobaplatin.